A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Trial Details

NCT ID

NCT06363825

Phase

PHASE2

Sponsor

Fujian Medical University

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

• camrelizumab

Locations (sample)

• Fuzhou, China|26.06139,119.30611

Key Eligibility Criteria

• 1\. The subjects voluntarily joined the study, had good compliance, cooperated with follow-up, and obtained written informed consent;
• 2\. Age: 18 years old ≤80 years old, both male and female;
• 3\. In accordance with the "Norms for the Diagnosis and Treatment of Primary Liver Cancer (2022 edition)" formulated by the National Health Commiss…
• 4\. There is at least one measurable lesion (spiral CT scan diameter ≥10mm or malignant lymph node short diameter ≥15mm according to RECIST1.1 stan…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.